Gufic Biosciences enters into research and collaboration agreement with Selvax

10 Mar 2022 Evaluate

Gufic Biosciences is entering into a research and collaboration agreement with Selvax, a biotechnology Company based in Perth, Western Australia, to accelerate the commercialization of Selvax's cancer immunotherapy treatment. Orbit Financial Capital, a boutique investment banking firm with a strong foothold in corporate finance, transaction advisory services, and debt syndication services, acts as the exclusive financial advisor to the transaction.

Under this initiative, Gufic will undertake mutually agreed development activities in return for the exclusive commercial rights for Selvax immunotherapy in India along with an equal share of future revenues that might be derived from future sales of the product in Europe, subject to the approvals received from the regulatory authorities in India and Europe, respectively. Selvax considers Gufic as an ideal collaboration partner on account of Gufic's long track record of innovation and new drug development. Gufic continues its efforts to bring innovation in the medical field by expanding its portfolio in cancer immunotherapy, which is one of the most rapidly growing segments of the global pharmaceutical market.

Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.

Gufic Biosciences Share Price

441.05 2.65 (0.60%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.